Ewha University-Industry Collaboration Foundation

Vasthera Co. Ltd.

The Catholic University of Korea Industry-Academic Cooperation Foundation

Wonmedical Corp.

Sang Won Kang

Kihwan Kwon

Dong Hoon Kang

Doo Jae Lee

Jeong Woo Lee

Ki Hwan Kwon

Soo Young Lee

Tae Suk Suh

Min Young Lee

Ji Yeon Park

Joon Yong Choi

Hae Jin Park

The present invention relates to a pharmaceutical composition for treating colorectal cancer including a material inhibiting the enzyme activity of peroxiredoxin 2 as an active ingredient, and more specifically, to a pharmaceutical composition for treating colorectal cancer, which exhibits the effect of reducing colon polyps via increase of active &#x3b2;-catenin degradation by inhibiting the activity of peroxiredoxin 2, based on the mechanism that promotes colorectal tumor by the interaction between peroxiredoxin 2 (PrxII) and tankyrase (TNKS) in an APC-mutant cell.

Pharmaceutical composition comprising substance inhibiting enzymatic activity of peroxiredoxin 2 as effective ingredient for treatment of colorectal cancer

The present invention relates to a pharmaceutical composition for preventing or treating pulmonary arterial hypertension, which comprises an epidithiodioxopiperazine (ETP) compound or a derivative thereof, or a pharmaceutically acceptable salt thereof.

Pharmaceutical composition comprising epidithiodioxopiperazine compound or derivative thereof, or pharmaceutically acceptable salt thereof, for preventing or treating pulmonary hypertension

Provided are a composition for diagnosing vascular disease including an agent measuring a level of interleukin 12 receptor &#x3b2;2 protein in the blood, and a kit for diagnosing vascular disease including the same. Further, provided is a method for diagnosing vascular disease, the method including the step of measuring a level of interleukin 12 receptor &#x3b2;2 protein in a blood sample separated from an individual suspected of having vascular disease. Furthermore, provided are a composition for preventing or treating vascular disease including an interleukin 12 receptor &#x3b2;2 activity inhibitor, and a method of screening a therapeutic agent for vascular disease, the method including the step of treating smooth muscle cells with a test agent for vascular disease treatment and measuring an expression level of interleukin 12 receptor &#x3b2;2.

Biomarker for diagnosing vascular diseases and the uses thereof

The present invention relates to an epidithiodioxopiperazine derivative represented by the following Chemical Formula 1 or its reduced derivative; a method for preparing a compound represented by Chemical Formula 1 having improved intracellular permeability and mimicking the activity of 2-Cys-Prx in its reduced form in the cells; a pharmaceutical composition for preventing or treating vascular diseases comprising an epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient; a drug delivery device for local administration including the pharmaceutical composition; and a pharmaceutical composition for inhibiting melanoma metastasis comprising the epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient. 

Epidithiodioxopiperazine compound or its derivatives, and the use thereof

The present invention relates to a head and neck simulation phantom device for simulating the head and neck of a body, the phantom device including: a flat type first plate having a first insertion groove formed on one surface thereof; a flat type second plate disposed to come into contact with the other surface of the first plate and having a second insertion groove formed on the contacted surface with the other surface of the first plate in such a manner as to correspond to the first insertion groove; and a plurality of teeth simulants inserted into the first insertion groove and the second insertion groove and for simulating the teeth of the body.

Head and neck simulation phantom device

The present invention relates to a pharmaceutical composition for preventing or treating diseases related to abnormal proliferation of cells, comprising a cytoplasmic heat shock protein (Hsp)60 kDa inhibitor as an active ingredient, and to a screening method and a kit using the composition. According to the present invention, substances which inhibit expression of cytoplasmic Hsp 60 genes or inhibit activity of cytoplasmic Hsp 60 or inhibit binding between cytoplasmic Hsp 60 and IKK protein prevent interaction between cytoplasmic Hsp 60 and IKK complexes to make NF-&#x3ba;B path inactive, and thus induce apoptosis. Therefore, the substances can be valuably used in preventing or treating diseases related to abnormal proliferation of cells, such as cancer, inflammatory diseases or hyperproliferative vascular diseases.

Pharmaceutical composition for inhibiting abnormal proliferation of cells

The present invention relates to a method for inhibiting angiogenesis using a peroxiredoxin II (Prx II) inhibitor, and a method for preparing angiogenesis-inhibiting medicines using Prx II inhibitor. According to the present invention, the inhibitor of Prx II gene expression or Prx II protein activity increases oxidative inactivation of VEGF receptor tyrosine kinase (RTK) to reduce VEGF signaling, thereby screening a novel angiogenesis inhibitor. Therefore, the method of the present invention can be used for the prevention or treatment of various diseases, ailments, and conditions related to angiogenesis.

Growing community of inventors

Seoul, South Korea

Sang Won Kang